ACBI2
Product Specifications
UNSPSC Description
ACBI2 is a highly potent and orally active VHL PROTAC SMARCA2 degrader (EC50: 7 nM), which selectively degrades SMARCA2 with a DC50 value of 1 nM in RKO cells. ACBI2 can be used in the research of lung cancer[1].
Target Antigen
Epigenetic Reader Domain; PROTACs
Type
Reference compound
Related Pathways
Epigenetics;PROTAC
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/acbi2.html
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
BrC1=CC=CC(N(C2=CC=C(C3CCN(CC[C@@H](C)CC[C@@H](C4=CC=C(C5=C(C)N=CS5)C=C4)NC([C@@H]6C[C@@H](O)CN6C([C@H](C(C)(C)C)NC(C7(CC7)F)=O)=O)=O)CC3)C=C2N8C9CCCC9)C8=N%10)=C1C%10=O
Molecular Weight
1064.16
References & Citations
[1]Kofink C, et al. A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo. Nat Commun. 2022 Oct 10;13(1):5969.
Shipping Conditions
Blue Ice
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-151623/ACBI2-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-151623/ACBI2-SDS-MedChemExpress.pdf
Clinical Information
No Development Reported
CAS Number
2913161-19-8
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
